<iframe src="https://www.googletagmanager.com/ns.html?id=GTM-PHTV9K7" height="0" width="0" style="display:none;visibility:hidden">
Loading
Skip to Main Content
Product cover image for DOES: Commercializing AI in Regulated Pharma Manufacturing

DOES: Commercializing AI in Regulated Pharma Manufacturing

Carmen Ocasio Rodriguez, Neha Mittal

Product #:W46487
Supplier:Ivey/Temple
Discipline:Operations Management, Strategy
Setting:United States, 2025
Details:Case (PDF) • 11 pages • 2026-01-08

Subjects:

Change managementBusiness managementOperations and supply chain managementOperations and supply chain managementStrategy

Industries:

Healthcare sectorHealthcare sector

Geography:

United StatesNorth AmericaUnited States
Your Price:$10.54

Purchase this material with a free Educator Account and enjoy more benefits:

  • Free Educator Copy
  • Free Teaching Notes
  • Build your coursepack
  • Discounted academic price

AWARD WINNER - 2025 Fox International Case Writing Competition


By mid-2025, Defense Operations & Engineering Inc. (DOES), a start-up based in Melbourne, Florida, and founded by Aaron Sneed, had developed a cutting-edge AI-driven smart manufacturing platform aimed at reshoring active pharmaceutical ingredient (API) production. The platform could personalize medications and optimize manufacturing in real time, but it lacked approval by the U.S. Food and Drug Administration (FDA), limiting its commercial rollout. With only US$5 million in capital and 14–18 months of runway left, Sneed faced a strategic dilemma: invest further in AI development to stay technologically ahead, prioritize regulatory compliance to speed up market entry, adopt a hybrid approach, or form partnerships to share costs and risks. The case explores the challenges of commercializing AI in a heavily regulated industry, balancing innovation with compliance, and making high-stakes decisions under financial constraints.

Learning Objectives

This case is best used for students in an undergraduate- or graduate-level course focused on strategy, innovation management, health sector entrepreneurship, or regulatory affairs. It challenges students to examine the strategic and operational dilemmas faced by an AI-driven start-up in the highly regulated pharmaceutical manufacturing industry. It aligns with the AI, analytics, and automation theme by exploring how emerging technologies can transform supply chains, while highlighting the real-world challenges of scaling innovation, navigating compliance, and building market credibility in a data-intensive industry.

The case addresses how a mission-driven start-up navigates the commercialization of advanced technologies in a highly regulated and resource-constrained environment. This case will challenge students to think critically about strategic decision-making, compliance, and partnerships in the context of health care innovation. After working through the case and assignment questions, students will be able to do the following:

  • Analyze how start-ups navigate critical decision points between innovation, regulatory compliance, and time-to-market, particularly in capital-constrained environments.
  • Explore how regulatory frameworks like the FDA’s current good manufacturing practice and AI-specific guidance influence the development, approval, and deployment of innovations in health technology.
  • Design go-to-market strategies for health sector start-ups.
  • Assess how adaptive AI systems can be both an opportunity and liability in pharmaceutical manufacturing, and how start-ups can structure operations to meet evolving compliance standards without losing their technological edge.
Loading
Case Study: DOES: Commercializing AI in Regulated Pharma Manufacturing (English version) | Ivey Publishing